NPI registry status
Active
2026 NPPES data Interventional Pain Medicine Physician NPI 1417091133 M.D.
Verify on CMS → Michael Shahbazian, M.D.
Interventional Pain Medicine Physician in Newport Beach, California.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 1,528 in Interventional Pain Medicine Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
2K
Medicare Part D claims · 287 beneficiaries · Interventional Pain Medicine Physician avg: 2K
Generic prescribing
97%
generic claims · 3% brand-name · higher generic rates reduce patient out-of-pocket costs
Source: CMS Medicare Part D Prescriber Public Use File, 2023
Compiled from official public sources by the PlainDoctor editorial team.
What the federal data shows
Michael Shahbazian, M.D. filed 1,716 Medicare Part D claims in 2023 as a Interventional Pain Medicine Physician in Newport Beach, California, prescribing 97% generic.
- 2K
- Part D claims, 2023
- 97%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Michael Shahbazian, M.D.'s Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2023, across all CMS prescribers nationally
1,716 Top 17% higher than 83% of 1,370,886 prescribers
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Medicare Part D Prescriber Public Use File · 2023
✓
Board certification likely (heuristic, not verified)
Michael Shahbazian, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + 1 hospital affiliation - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Michael Shahbazian, M.D.?
Quality data not reportedPrimary specialty
Interventional Pain Medicine Physician
Medicare Part D claims
1,716 22% vs specialty avg
Specialty distribution in California
How Interventional Pain Medicine Physician compares to other specialties among California providers
Board certification
Not published by CMS
CMS does not publish a per-provider board-certification field in NPPES. PlainDoctor does not have a reliable per-specialty certification rate to show for Interventional Pain Medicine Physician. Verify directly:
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Michael Shahbazian, M.D. appears in the CMS NPPES registry as a Interventional Pain Medicine Physician provider holding M.D. credentials at 366 SAN MIGUEL DR STE 210, Newport Beach, CA, 92660, with a listed phone of (949) 207-9494. NPI 1417091133 was issued on 02/16/2007.
Medicare Part D records for calendar year 2023 show 1,716 prescription claims written by this provider, covering 287 Medicare beneficiaries and totaling roughly $61K in drug spend, split 3% brand-name and 97% generic by claim count, with an opioid prescribing rate of 47.6%.
Interventional Pain Medicine Physician is a narrow specialty nationwide, with 1,528 enrolled providers across 53 states and an average of 2,197 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.
Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1417091133 |
|---|---|
| Specialty | Interventional Pain Medicine Physician |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 02/16/2007 |
Hospital and facility affiliations
Facilities where Michael Shahbazian, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Afshin Gerayli MD A Professional Corporation
Irvine, CA
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
License & disciplinary context - California MBC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 - they are NOT specific to Michael Shahbazian, M.D.. To verify Michael Shahbazian, M.D.'s current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
576
Total board actions, California 2023
Across 556 cases
3.84
Actions per 1,000 licensees
California statewide rate
probation
Most common action type
186 cases
MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Generic-heavy
Michael Shahbazian, M.D. - brand share 3.0%
Interventional Pain Medicine Physician average
3% brand-name claims vs 97% generic, on 1,716 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
1,716
Total Claims
$61K
Total Drug Cost
287
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 1,846
- Total Day Supply
- 50,918
- Brand vs Generic
- 3% brand / 97% generic
- Brand Drug Cost
- $17K
- Generic Drug Cost
- $43K
- Opioid Claims
- 817 (47.6% rate)
Patient Demographics
- Average Patient Age
- 70.7 years
- Avg HCC Risk Score
- 2.07
- Gender Split
- 64% female / 36% male
- Age Distribution
- <65: 51, 65-74: 145, 75-84: 70, 85+: 21
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Michael Shahbazian, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Hydrocodone-Acetam…
Hydrocodone-Acetaminophen
305 claims
- Gabapentin
Gabapentin
198 claims
- Tramadol Hcl
Tramadol Hcl
165 claims
- Oxycodone-Acetamin…
Oxycodone-Acetaminophen
129 claims
- Pregabalin
Pregabalin
124 claims
- Diclofenac Sodium 94
Diclofenac Sodium
94 claims
- Oxycodone Hcl 88
Oxycodone Hcl
88 claims
- Meloxicam 68
Meloxicam
68 claims
| Drug | Claims |
|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 305 |
| Gabapentin | 198 |
| Tramadol Hcl | 165 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 129 |
| Pregabalin | 124 |
| Diclofenac Sodium | 94 |
| Oxycodone Hcl | 88 |
| Meloxicam | 68 |
| Cyclobenzaprine Hcl | 65 |
| Naloxone Hcl | 63 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
More Interventional Pain Medicine Physician in CA →
All providers in California →
Compare specialties →
Interventional Pain Medicine Physician Overview
How Michael Shahbazian, M.D. fits within the Interventional Pain Medicine Physician landscape nationally.
1,528
Interventional Pain Medicine Physician Providers in US
53
States with Interventional Pain Medicine Physician
2,197
Avg Claims per Provider
Michael Shahbazian, M.D.'s 1,716 claims are below the specialty average of 2,197.
Nearby Interventional Pain Medicine Physician Providers in California
Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as Shahbazian.
Dr. Hussein Abdulhadi
M.D.
La Mesa, CA
Dr. Nader Achackzad
M.D.
Santa Clara, CA
Dr. Patrick Akin
DO
Turlock, CA
Dr. Kais Alsharif
MD
Long Beach, CA
Dr. Pari Azari
M.D.
Clearlake, CA
Compare Interventional Pain Medicine Physician nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the California medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Interventional Pain Medicine Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
How to Find a Doctor
Step-by-step guide to choosing a provider
Verify Credentials
Check NPI, board certification & license status
Medical Specialties Explained
Who treats what and how specialties differ
Understanding Medicare Claims Data
What prescribing data reveals about a provider
In-Network vs Out-of-Network
How insurance networks affect your costs
Telehealth Guide
Virtual care options and coverage in 2026
Explore California
Frequently Asked Questions
What is Michael Shahbazian, M.D.'s specialty? ▼
Michael Shahbazian, M.D. specializes in Interventional Pain Medicine Physician and practices in Newport Beach, California. Credentials: M.D..
How much does Michael Shahbazian, M.D. prescribe under Medicare Part D? ▼
In 2023, Michael Shahbazian, M.D. wrote 1,716 Medicare Part D claims totaling $61K in drug costs for 287 beneficiaries.
Where is Michael Shahbazian, M.D. located? ▼
Michael Shahbazian, M.D. is located at 366 SAN MIGUEL DR STE 210, Newport Beach, CA, 92660. Phone: (949) 207-9494.
What is Michael Shahbazian, M.D.'s NPI number? ▼
Michael Shahbazian, M.D.'s National Provider Identifier (NPI) is 1417091133, issued on 02/16/2007.
Does Michael Shahbazian, M.D. prescribe more brand-name or generic drugs? ▼
Michael Shahbazian, M.D.'s prescribing is 3% brand-name and 97% generic drugs by claim count, with $17K in brand drug costs.
Does Michael Shahbazian, M.D. prescribe opioids? ▼
Yes, Michael Shahbazian, M.D. had 817 opioid claims in 2023 with an opioid prescribing rate of 47.6%.
How many Interventional Pain Medicine Physician providers are there in the US? ▼
There are 1,528 Interventional Pain Medicine Physician providers across 53 states in the US. The average Interventional Pain Medicine Physician provider writes 2,197 Medicare Part D claims per year.
What drugs does Michael Shahbazian, M.D. prescribe most often? ▼
Based on 2023 Medicare Part D data, Michael Shahbazian, M.D.'s most frequently prescribed drugs include Hydrocodone-Acetaminophen, Gabapentin, Tramadol Hcl. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Michael Shahbazian, M.D. accept Medicare? ▼
Michael Shahbazian, M.D. appears in CMS Medicare data with 1,716 Part D claims and 287 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Michael Shahbazian, M.D.'s credentials? ▼
Michael Shahbazian, M.D.'s NPI is 1417091133 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Compiled from official public sources by the PlainDoctor editorial team.